Newsroom - ponstreatment

Press Releases

Helius Medical Technologies (Canada) Join Forces With Brainfx to Create Educational Awareness on Innovative Treatment and Assessments in Brain Health

Oct 28 2020
Helius Medical Technologies, Inc. Announces Publication of Peer-Reviewed Study: Translingual Neural Stimulation with the Portable Neuromodulation Stimulator (PoNS™) Induces Structural Changes Leading to Functional Recovery in Patients with Mild-to-Moderate Traumatic Brain Injury

Sep 08 2020
Helius Medical Technologies, Inc. Announces FDA Has Granted the PoNS Device Breakthrough Device Designation for the Treatment of Gait Deficits Due to Symptoms of Multiple Sclerosis

May 12 2020

VIEW ALL RELEASES

In the News

MS Connect Breakout Session: Taking Charge of MS: Hear From a PoNS™ Patient

Nov 28 2020
MS Connect Breakout Session: What is PoNS Treatment™? Using the Tongue as a Superhighway to the Brain

Nov 25 2020
PoNS Therapy Helps Ontario Woman Recover From Brain Injury

Oct 15 2020

SEE ALL COVERAGE

Resources

Media Kit	Download
PoNS™ Logo	Download

Quick Links

Frequently Asked Questions	> > >
Patient and Clinician Testimonials	> > >
Clinical Evidence	> > >

Social Media Accounts

Media Contact

Have a media inquiry? Contact us!

Melissa Durrell
This email address is being protected from spambots. You need JavaScript enabled to view it.

PoNS and PoNS Treatment are trademarks of Helius Medical, Inc

Regulatory Disclaimer
Privacy Policy

QUICK LINKS

PoNS™ is an authorized medical device and commercially available in Canada. PoNS™ is an investigational device in the US, EU, and Australia and is currently under review for market clearance by the AUS TGA; PoNS™ is not commercially available in the US, EU, or Australia.

The device is intended for use as a short term treatment (14 weeks) of chronic balance deficit due to mild-to-moderate traumatic brain injury and is to be used in conjunction with physical therapy. The device is intended for use as a short term treatment (14 weeks) of gait deficit due to mild and moderate symptoms from MS and is to be used in conjunction with physical therapy.